Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.
about
Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant SchizophreniaFactors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system.Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injectionEfficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.Premorbid personality and insight in first-episode psychosis.Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisTreatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence.Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia[Risk factors for treatment adherence in patients with schizophrenia: case-control study].Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa.Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesPsychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia-Pacific surveyPerspectives on medicine adherence in service users and carers with experience of legally sanctioned detention and medication: a qualitative studyTen year neurocognitive trajectories in first-episode psychosisMobile phone text message reminders of antipsychotic medication: is it time and who should receive them? A cross-sectional trust-wide survey of psychiatric inpatients.Pharmacological treatment of schizophrenia.Improving treatment adherence in your patients with schizophrenia: the STAY initiative.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.Antipsychotic medication in schizophrenia: a review.Nonadherence to immunosuppressive therapy in kidney transplant recipients: can technology help?Medication adherence in patients with schizophrenia.Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.Treatment engagement of psychotic patients with a mobile mental health unit in rural areas in Greece: a five-year study.Factors predicting the presence of impaired clinical insight in liaison psychiatric patients assessed in the Emergency Room.Effect of a system-oriented intervention on compliance problems in schizophrenia: a pragmatic controlled trial.Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients.Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.The meaning of pharmacological treatment for schizophrenic patients.Economic factors in of patients' nonadherence to antidepressant treatment.Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.Evaluation of medication compliance in patients on antidepressants at an outpatient tertiary cancer center setting.Treatment adherence and quality of sleep in schizophrenia outpatients.Psychotropic medication non-adherence and associated factors among adult patients with major psychiatric disorders: a protocol for a systematic review.
P2860
Q26773403-CDFB8E00-1FFC-4D34-9658-0F02EE437E36Q33713167-ED7E8998-569E-42A9-825B-61CDB31450DDQ33817737-30F49D49-2FE9-49D4-8E04-92BE315E1179Q34286350-238D1D4E-F500-4496-B5DE-5C124707B539Q34415919-C1E37846-42A4-459C-8B24-EA9B128F1DC5Q34560335-D3A39835-3F71-44ED-A670-8A96D6C2FF48Q34588656-0A4B43C6-FB93-417C-AB68-03BFC09EC9E9Q34855041-36940792-92FF-4559-9683-A3D6A96C3356Q34982167-771375C3-518A-4BB2-9327-208391458FEDQ35018988-5E644B96-B733-43DD-AB90-872026BB9FF1Q35186503-6332955A-566F-4172-9C49-A49B00710B8DQ35793302-931918C7-E112-4907-8625-EC95D536B91DQ35882300-C4EED6A5-1FF3-4894-A262-E64894F88414Q36353950-47931FEE-8771-473C-B6AE-02395C7FD096Q36489412-63C369C3-5EF6-40C8-AB19-A0C55B0C3D70Q36587739-E813E0EB-ECD5-4602-891F-538C94815805Q37042180-0BF9CAE7-DF68-4962-ABA3-E60A3ED65024Q37104411-2DE21269-2F4F-4560-B130-33902864E97DQ37109707-52C02A7B-718D-4F47-B033-9EBBDAE0CE74Q37217597-935D590D-71E2-4E1C-A867-5BB54883C749Q37580919-99AEB6CE-C373-401A-AE51-91206D6AB484Q38051438-26716AC7-08BB-451A-9779-ABEA3139383DQ38071595-A772434C-B849-4606-8E68-986ECD9E9B93Q38233228-398CE6DA-73B0-434C-9573-B0D4E19C119FQ38468745-DB242A5C-12BD-4D74-93EA-EFA0D04C52ACQ38736961-9F718883-5936-4BA8-A892-09D7A31402FDQ38808583-F31F8C05-8608-451A-8F83-F84C34BE6872Q39233956-96248476-CDDA-4D30-B964-ABFCE54FAF58Q39289346-BAAED0D4-983D-4630-8032-8DA8F841CBDAQ40149846-C3C8E331-F2E0-43DF-B5B7-9E083A3F21C3Q40426406-AD4230FD-8BF8-42B2-B2D1-AE7C17B75F49Q40785183-1AA97FCC-A7FE-4B97-AE40-BE40FED60F65Q42088414-C91274F7-57E8-4232-BA11-82BD57061C47Q42149681-C4F7D72A-AE58-40EC-8B8E-066CE8B4A610Q42687191-87D2A981-9DF3-446C-BB16-AF6B7899F63FQ43443984-14D5EF53-E9D4-48CE-BA1A-C2FCE0F2C353Q43926986-0DEF088A-E10F-4D09-8596-D53EF56CCD54Q46129677-FD030A90-7F99-4887-B682-8FCD5C5E6491Q46310744-1BA3B313-9E09-4366-9E2E-109D98BD55FFQ47555919-ECB63554-1EF3-46AC-82FD-E5323D9FE9FF
P2860
Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Partial adherence to antipsych ...... with schizophrenia: a review.
@en
Partial adherence to antipsych ...... with schizophrenia: a review.
@nl
type
label
Partial adherence to antipsych ...... with schizophrenia: a review.
@en
Partial adherence to antipsych ...... with schizophrenia: a review.
@nl
prefLabel
Partial adherence to antipsych ...... with schizophrenia: a review.
@en
Partial adherence to antipsych ...... with schizophrenia: a review.
@nl
P2093
P2860
P356
P1476
Partial adherence to antipsych ...... with schizophrenia: a review.
@en
P2093
John M Kane
Martin S Turner
Prakash S Masand
P2860
P304
P356
10.4088/PCC.08R00612
P50
P577
2009-01-01T00:00:00Z